key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
Published 1 year ago • 2K plays • Length 13:39Download video MP4
Download video MP3
Similar videos
-
1:02
emerging treatment options for lower- and higher-risk mds and ongoing trials
-
3:19
key clinical trials in mds taking place in the us
-
1:20
the current standard of care for patients with lower-risk mds
-
1:59
the role of inflammatory signaling pathways in lower-risk mds
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:21
hmas for mds- a party of one
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
1:34:29
aml'de flt3 mutasyonları ve ötesi. klinik uygulamalarımızda genetik nerede?
-
4:16
how are high risk and low risk mds defined? #mds
-
4:48
managing and treating mds
-
1:52
advances in lr-mds and hr-mds in 2023 and beyond
-
13:31
key highlights in mpns: novel agents, combinations, and the potential role of immunotherapy
-
16:35
key highlights in mpns at ash 2023: novel agents & combinations, ongoing clinical trials, and more
-
1:45
a phase ii study of elritercept for lower-risk mds
-
1:45
updates on the treatment of mds
-
1:32
next-generation sequencing for low-risk mds
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
1:16
state of the art: mds
-
1:04
the current standard of care for mds-related cytopenias and how treatment strategies may evolve
-
2:16
current and future treatment approaches for hr-mds
-
0:45
current landscape of treatment for scd: an update from ash 2023